SCHEMBL17599348

SCHEMBL17599348

Cc1cc(NC(=O)N2CCOCC2)ccc1S(=O)(=O)Nc1ccc(-c2cccc(C(=O)O)c2)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
NPY5R Q15761 6/20 0.45
MCL1 Q07820 2/20 0.45
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 5/20 0.42
KDM4E B2RXH2 3/20 0.42
TP53 P04637 1/20 0.42
PIK3C2B O00750 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAP1LC3B Q9GZQ8 1/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CCR8 P51685 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599328 0.84 NR1H4 (0.53) NPC1RAB9AMCL1ALDH1A1SMN1; SMN2
SCHEMBL17613322 0.82 RAB9A (0.44) NPC1RAB9ANPY5RALDH1A1SMN1; SMN2
SCHEMBL17599301 0.78 KMT2A (0.48) MCL1ALDH1A1MEN1KMT2AMAPT
SCHEMBL17599351 0.73 KMT2A (0.45) NPC1RAB9AMCL1SMN1; SMN2MEN1
SCHEMBL17599371 0.73 KMT2A (0.51) MCL1ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL17599404 0.73 KMT2A (0.48) MCL1ALDH1A1MEN1KMT2ALMNA
SCHEMBL17599389 0.72 TDP1 (0.53) NPC1RAB9AMCL1ALDH1A1KDM4E
SCHEMBL17599329 0.72 KMT2A (0.55) MCL1ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL26664991 0.71 POLB (0.52) NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL26657089 0.71 POLB (0.59) KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed